DDInter1042 DDInter737
Leuprolide is a synthetic 9-residue peptide analogue of gonadotropin-releasing hormone (GnRH). Unlike the endogenous decapeptide GnRH, leuprolide contains a single D-amino acid (D-leucyl) residue, which helps to increase its circulating half-life from three to four minutes to approximately three hours. As a GnRH mimic, leuprolide is capable of binding to the GnRH receptor (GnRHR) and inducing downstream modulation of both gonadotropin hormone and sex steroid levels. Prolonged activation of GnRHR results in significant downregulation of sex steroid levels, which is primarily responsible for the clinical efficacy of leuprolide in diverse conditions, including advanced prostate cancer, endometriosis, and central precocious puberty.[A203126, A203132] Leuprolide was first approved in 1985 as a daily subcutaneous injection under the tradename
Multiple sclerosis, or MS, is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis. It was developed by Novartis and initially approved by the FDA in 2010. Fingolimod was also studied for the treatment of COVID-19, the disease caused by infection with the SARS-CoV-2 virus.[L12654,L12657]
Fingolimod {u} (Compound) treats {v} (Disease) multiple sclerosis
Fingolimod {u} (Compound) binds {v} (Gene) S1PR4
Fingolimod {u} (Compound) is included by {v} (Pharmacologic Class) Sphingosine 1-Phosphate Receptor Modulators
Fingolimod {u} (Compound) causes {v} (Side Effect) Cardiac arrest
Fingolimod {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sulfamethoxazole
Fingolimod {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Olodaterol
Fingolimod {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Olanzapine
Fingolimod {u} may lead to a major life threatening interaction when taken with {v} Tizanidine
Fingolimod {u} may lead to a major life threatening interaction when taken with {v} Tofacitinib
Fingolimod (Compound) treats multiple sclerosis (Disease)
Fingolimod (Compound) binds S1PR4 (Gene)
Fingolimod (Compound) is included by Sphingosine 1-Phosphate Receptor Modulators (Pharmacologic Class)
Fingolimod (Compound) causes Cardiac arrest (Side Effect)
Fingolimod may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole
Fingolimod may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol
Fingolimod may cause a moderate interaction that could exacerbate diseases when taken with Olanzapine
Fingolimod may lead to a major life threatening interaction when taken with Tizanidine
Fingolimod may lead to a major life threatening interaction when taken with Tofacitinib